Chugai OTC Stock Today

CHGCF -  USA Stock  

USD 32.52  3.72  10.26%

Market Performance
0 of 100
Odds Of Distress
Less than 46
Chugai Pharmaceutical is trading at 32.52 as of the 4th of December 2021, a -10.26 percent decrease since the beginning of the trading day. The stock's lowest day price was 32.52. Chugai Pharmaceutical has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Chugai Pharmaceutical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of January 2021 and ending today, the 4th of December 2021. Click here to learn more.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. The company has 1.64 B outstanding shares. More on Chugai Pharmaceutical
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Chugai Pharmaceutical OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Chugai Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Chugai Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chugai Pharmaceutical generated a negative expected return over the last 90 days
About 60.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases - Yahoo Finance
Legal NameChugai Pharmaceutical
Chairman and CEOOsamu Nagayama  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Chugai Pharmaceutical's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Chugai Pharmaceutical [CHGCF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Large-Cap' category with current market capitalization of 54.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chugai Pharmaceutical's market, we take the total number of its shares issued and multiply it by Chugai Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Chugai Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.64 B outstanding shares. Chugai Pharmaceutical has accumulated about 391.23 B in cash with 252.66 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 237.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Chugai Pharmaceutical Probability Of Bankruptcy
Ownership
Chugai Pharmaceutical retains a total of 1.64 Billion outstanding shares. Chugai Pharmaceutical shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 60.17 percent of Chugai Pharmaceutical outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Chugai Ownership Details

Chugai Stock Price Odds Analysis

What are Chugai Pharmaceutical's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Chugai Pharmaceutical jumping above the current price in 90 days from now is about 98.0%. The Chugai Pharmaceutical probability density function shows the probability of Chugai Pharmaceutical otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Chugai Pharmaceutical has a beta of 0.8313 suggesting as returns on the market go up, Chugai Pharmaceutical average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Chugai Pharmaceutical will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Chugai Pharmaceutical is significantly underperforming DOW.
 Odds Down 32.52HorizonTargetOdds Up 32.52 
1.90%90 days
 32.52 
98.07%
Based on a normal probability distribution, the odds of Chugai Pharmaceutical to move above the current price in 90 days from now is about 98.0 (This Chugai Pharmaceutical probability density function shows the probability of Chugai OTC Stock to fall within a particular range of prices over 90 days) .

Chugai Pharmaceutical Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Chugai Pharmaceutical market risk premium is the additional return an investor will receive from holding Chugai Pharmaceutical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Chugai Pharmaceutical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Chugai Pharmaceutical's alpha and beta are two of the key measurements used to evaluate Chugai Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.

Chugai Stock Against Markets

Picking the right benchmark for Chugai Pharmaceutical otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Chugai Pharmaceutical otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Chugai Pharmaceutical is critical whether you are bullish or bearish towards Chugai Pharmaceutical at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chugai Pharmaceutical without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Chugai Pharmaceutical Corporate Directors

Chugai Pharmaceutical corporate directors refer to members of a Chugai Pharmaceutical board of directors. The board of directors generally takes responsibility for the Chugai Pharmaceutical's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Chugai Pharmaceutical's board members must vote for the resolution. The Chugai Pharmaceutical board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Masayuki Oku - Independent DirectorProfile
Franz Humer - Independent DirectorProfile
Sophie KornowskiBonnet - Independent DirectorProfile
Yasuo Ikeda - Independent DirectorProfile
Continue to Trending Equities. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Chugai OTC Stock analysis

When running Chugai Pharmaceutical price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Chugai Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chugai Pharmaceutical. If investors know Chugai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chugai Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chugai Pharmaceutical is measured differently than its book value, which is the value of Chugai that is recorded on the company's balance sheet. Investors also form their own opinion of Chugai Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Chugai Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chugai Pharmaceutical's market value can be influenced by many factors that don't directly affect Chugai Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chugai Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Chugai Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chugai Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.